333 related articles for article (PubMed ID: 29038270)
1. Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.
Weiss WJ; Pulse ME; Nguyen P; Peterson K; Silva J; Simecka JW; Valtierra D; Sabet M; Griffith DC
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038270
[TBL] [Abstract][Full Text] [Related]
2. Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.
Sabet M; Tarazi Z; Nolan T; Parkinson J; Rubio-Aparicio D; Lomovskaya O; Dudley MN; Griffith DC
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109160
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem.
Griffith DC; Sabet M; Tarazi Z; Lomovskaya O; Dudley MN
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397063
[TBL] [Abstract][Full Text] [Related]
4. Meropenem-vaborbactam for the treatment of complicated urinary tract infections including acute pyelonephritis.
Wu G; Cheon E
Expert Opin Pharmacother; 2018 Sep; 19(13):1495-1502. PubMed ID: 30160990
[TBL] [Abstract][Full Text] [Related]
5. Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae.
Jorgensen SCJ; Rybak MJ
Pharmacotherapy; 2018 Apr; 38(4):444-461. PubMed ID: 29427523
[TBL] [Abstract][Full Text] [Related]
6. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae.
Lee YR; Baker NT
Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1411-1419. PubMed ID: 29675787
[TBL] [Abstract][Full Text] [Related]
7. Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria.
Patel TS; Pogue JM; Mills JP; Kaye KS
Future Microbiol; 2018 Jul; 13(9):971-983. PubMed ID: 29692218
[TBL] [Abstract][Full Text] [Related]
8. Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections.
Dhillon S
Drugs; 2018 Aug; 78(12):1259-1270. PubMed ID: 30128699
[TBL] [Abstract][Full Text] [Related]
9. Effects of KPC Variant and Porin Genotype on the
Wilson WR; Kline EG; Jones CE; Morder KT; Mettus RT; Doi Y; Nguyen MH; Clancy CJ; Shields RK
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617090
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M
Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
[TBL] [Abstract][Full Text] [Related]
11. Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae.
Castanheira M; Huband MD; Mendes RE; Flamm RK
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652234
[TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance.
Kinn PM; Chen DJ; Gihring TM; Schulz LT; Fox BC; McCreary EK; Lepak AJ
Diagn Microbiol Infect Dis; 2019 Mar; 93(3):258-260. PubMed ID: 30344065
[TBL] [Abstract][Full Text] [Related]
13. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
[TBL] [Abstract][Full Text] [Related]
14. Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections.
Albin OR; Patel TS; Kaye KS
Expert Rev Anti Infect Ther; 2018 Dec; 16(12):865-876. PubMed ID: 30372359
[TBL] [Abstract][Full Text] [Related]
15. Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant
Athans V; Neuner EA; Hassouna H; Richter SS; Keller G; Castanheira M; Brizendine KD; Mathers AJ
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30578403
[TBL] [Abstract][Full Text] [Related]
16. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
17. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.
Lomovskaya O; Sun D; Rubio-Aparicio D; Nelson K; Tsivkovski R; Griffith DC; Dudley MN
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848018
[TBL] [Abstract][Full Text] [Related]
18. Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC.
Barnes MD; Taracila MA; Good CE; Bajaksouzian S; Rojas LJ; van Duin D; Kreiswirth BN; Jacobs MR; Haldimann A; Papp-Wallace KM; Bonomo RA
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182530
[TBL] [Abstract][Full Text] [Related]
19. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
Ackley R; Roshdy D; Meredith J; Minor S; Anderson WE; Capraro GA; Polk C
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094128
[TBL] [Abstract][Full Text] [Related]
20. Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an
Sabet M; Tarazi Z; Rubio-Aparicio D; Nolan TG; Parkinson J; Lomovskaya O; Dudley MN; Griffith DC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
